The clinical success of olaparib and the discovery of tumours with molecular and clinical features similar to gBRCAm-associated tumours, prompted the clinical development of various PARP inhibitors either as single agents or as part of combined treatment with DNA damaging agents in phase I and II clinical trials. The gene discussed is PARP1; the disease is neoplasm.